Improving Outcomes for Patients Through the Optimal Integration of HER2-Targeted Antibody–Drug Conjugate Therapy

Explore expert insights on the optimal utilization of HER2-targeted ADCs in patients with advanced NSCLC in an on-demand webcast derived from a live event. Then, download the accompanying slides for a comprehensive reference on the latest advancements in treatment strategies.

Share

Program Content

Activities

HER2-Targeted Therapy in NSCLC
Improving Outcomes for Patients With Advanced NSCLC Through the Optimal Integration of HER2-Targeted Antibody–Drug Conjugate Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 25, 2023

Activities

HER2-Targeted Therapy for NSCLC
Improving Outcomes for Patients With Advanced NSCLC Through the Optimal Integration of HER2-Targeted Antibody–Drug Conjugate Therapy
Video
Congratulations: You achieved a completion on 04/09/2022

Released: December 01, 2023

Expires: November 30, 2024

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.